For Hockey Players, Brain Damage Can Be Measured in Blood
Researchers have found protein traces of brain damage in the blood of hockey players who sustained a concussion. Could biomarkers help decide when athletes return to their sport?
588 RESULTS
Sort By:
Researchers have found protein traces of brain damage in the blood of hockey players who sustained a concussion. Could biomarkers help decide when athletes return to their sport?
The amyloid imaging agent florbetapir predicts cognitive decline much like its forerunner, PiB.
Low levels of 10 phospholipids in blood plasma correlated with future cognitive decline in older adults, hinting at diagnostic potential.
The first longitudinal data from DIAN conflict with some cross-sectional findings, revealing a small drop in CSF injury markers after the first appearance of symptoms of disease.
Detecting oligomers in the cerebrospinal fluid is no easy feat. The latest test is among the most sensitive yet, but is it useful?
Government, industry, and advocacy together will provide nearly $130 million for the identification of surrogate markers and targets.
Allegations of falsified data embroil Japanese ADNI; project leaders respond that data corrections followed quality-control procedures.
A combination of high clusterin and low Aβ42 in cerebrospinal fluid associates with early Alzheimer’s neurodegeneration, hinting at a mechanistic interaction between the proteins.
Evidence builds that amyotrophic lateral sclerosis and frontotemporal lobar degeneration sit on the same pathological spectrum, but scientists are unsure how the disease marker TDP-43 fits in.
A small panel of fluid biomarkers could predict a slow or fast disease course in amyotrophic lateral sclerosis.
In the early days of tau brain imaging, neurofibrillary pathology appears to match up with the subtle cognitive decline of presymptomatic Alzheimer’s.
People with neurodegeneration but not brain amyloid surface in two new studies of preclinical AD, suggesting this odd population is both legitimate and potentially large.
Tau fragments in cerebrospinal fluid might lead to better prognostic and diagnostic tests.
Among cognitively healthy older adults, the rate of change in cerebrospinal fluid biomarkers helps predict who will develop Alzheimer’s disease.
People who carry the Huntington’s gene develop progressively abnormal brain metabolism a decade or more before diagnosis.